CL2022000161A1 - Vacuna contra la peste porcina africana - Google Patents

Vacuna contra la peste porcina africana

Info

Publication number
CL2022000161A1
CL2022000161A1 CL2022000161A CL2022000161A CL2022000161A1 CL 2022000161 A1 CL2022000161 A1 CL 2022000161A1 CL 2022000161 A CL2022000161 A CL 2022000161A CL 2022000161 A CL2022000161 A CL 2022000161A CL 2022000161 A1 CL2022000161 A1 CL 2022000161A1
Authority
CL
Chile
Prior art keywords
seq
swine fever
african swine
asfv
polypeptides
Prior art date
Application number
CL2022000161A
Other languages
English (en)
Inventor
Linda Dixon
Chris Netherton
Geraldine Taylor
Dave Chapman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of CL2022000161A1 publication Critical patent/CL2022000161A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona una vacuna contra el virus de la peste porcina africana (ASFV) la cual comprende: (i) uno o más polinucleótidos recombinantes que codifican polipéptidos mostrados como las SEQ ID NO: 1, 2 y 3 o un fragmento inmunogénico de las mismas; o una variante con al menos un 70% de identidad de secuencia a uno de las SEQ ID NO: 1, 2 o 3; en la que el número total de diferentes polipéptidos de ASFV codificados por uno o más polinucleótidos recombinantes es de 10 o menos; o (ii) polipéptidos recombinantes mostrados como las SEQ ID NO: 1, 2 y 3 o un fragmento inmunogénico de las mismas; o una variante con al menos un 70% de identidad de secuencia a uno de las SEQ ID NO: 1, 2 y 3; en el que la vacuna comprende 10 o menos polipéptidos de ASFV diferentes.
CL2022000161A 2019-07-29 2022-01-24 Vacuna contra la peste porcina africana CL2022000161A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1910794.5A GB201910794D0 (en) 2019-07-29 2019-07-29 Vaccine

Publications (1)

Publication Number Publication Date
CL2022000161A1 true CL2022000161A1 (es) 2022-10-21

Family

ID=67990353

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000161A CL2022000161A1 (es) 2019-07-29 2022-01-24 Vacuna contra la peste porcina africana

Country Status (14)

Country Link
US (1) US20220273788A1 (es)
EP (1) EP4003412A1 (es)
JP (1) JP2022542174A (es)
KR (1) KR20220041144A (es)
CN (1) CN114375199A (es)
AU (1) AU2020322191A1 (es)
BR (1) BR112022000865A2 (es)
CA (1) CA3148586A1 (es)
CL (1) CL2022000161A1 (es)
CO (1) CO2022001782A2 (es)
GB (1) GB201910794D0 (es)
MX (1) MX2022001028A (es)
TW (1) TW202118771A (es)
WO (1) WO2021019232A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373119A (zh) * 2021-06-02 2021-09-10 江西农业大学 一种表达非洲猪瘟病毒三基因缺失重组伪狂犬病毒毒株、构建方法及其应用
CN116444653B (zh) * 2023-03-09 2024-03-15 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 一株阻断性非洲猪瘟病毒单克隆抗体杂交瘤细胞株的制备与应用
CN116284261B (zh) * 2023-04-04 2024-04-19 中国人民解放军军事科学院军事医学研究院 一种非洲猪瘟病毒结构蛋白组合物及其制备的疫苗

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2337113B1 (es) * 2007-04-17 2011-01-24 Centre De Recerca En Sanitat Animal (Cresa) Empleo de la hemaglutinina del virus de la peste porcina africana como adyuvante.
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
WO2017096341A2 (en) * 2015-12-04 2017-06-08 The Texas A&M University System Adenovirus-vectored multivalent vaccine
RU2654586C2 (ru) * 2016-04-20 2018-05-21 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии", (ФГБНУ ФИЦВиМ) Рекомбинационная кассета, содержащая гены EP153R и EP364R штамма Congo (КК-262) вируса африканской чумы свиней и рекомбинантный штамм ΔСongoCD2v вируса африканской чумы свиней

Also Published As

Publication number Publication date
KR20220041144A (ko) 2022-03-31
BR112022000865A2 (pt) 2022-03-08
GB201910794D0 (en) 2019-09-11
CO2022001782A2 (es) 2022-06-21
US20220273788A1 (en) 2022-09-01
EP4003412A1 (en) 2022-06-01
WO2021019232A1 (en) 2021-02-04
TW202118771A (zh) 2021-05-16
JP2022542174A (ja) 2022-09-29
CN114375199A (zh) 2022-04-19
CA3148586A1 (en) 2021-02-04
MX2022001028A (es) 2022-02-23
AU2020322191A1 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
CL2022000161A1 (es) Vacuna contra la peste porcina africana
MX2021011687A (es) Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas.
CO2022013121A2 (es) Vacuna 2019-ncov (sars-cov-2)
AR122899A1 (es) Combinación de vacunas
BR112017022298A2 (pt) geranilgeranil pirofosfato sintase
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ES2545895T3 (es) Proteína de fusión anticancerígena
BR112016001192A2 (pt) Vacina contra a raiva
EA038402B9 (ru) Аденовирусные полинуклеотиды и полипептиды
AR081856A1 (es) Vacuna y metodos para reducir una infeccion por campylobacter
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
PE20170906A1 (es) Alfa-glucosidasa acida muy potente con hidratos de carbono potenciados
AR113455A1 (es) Proteínas inmunomoduladoras de variantes del ligando de icos y composiciones y métodos relacionados
ES2676542T3 (es) Composiciones de CDV recombinante y usos de las mismas
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
PE20220429A1 (es) Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a
CL2022002416A1 (es) Vacuna
AR109538A1 (es) Vacuna contra la gripe porcina
EP2552490A4 (en) INFLUENZA MATRIX 2 PROTEIN ECKTOMOMAS, EXPRESSION SYSTEM THEREFOR AND USES THEREOF
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
MX2023000804A (es) Peptidos para usarse en la promocion del transporte de glucosa.
AR074055A1 (es) Vacuna contra el virus de la enfermedad del caballo africano. vector. peste equina. ahsp vp. polinucleotido aislado. metodo
AR100824A1 (es) Complejo de poliproteínas inmunogénicas de m. hyopneumoniae, gen sintético codificante del complejo de proliproteínas inmunogénicas de m. hyopneumoniae, composición antigénica, proceso de obtención de un complejo de poliproteínas inmunogénicas de m. hyopneumoniae, uso de una composición con base en el complejo de poliproteínas inmunogénicas de m. hyopneumoniae
AR091033A1 (es) Metodo para producir 11-des-o-metiltomaimicina recombinante
PH12020551944A1 (en) Reverse peptide vaccine